NCT03435939 is a EARLY_PHASE1 clinical trial of Losartan in Cystic Fibrosis, sponsored by University of Kansas Medical Center.

Who is sponsoring NCT03435939?

NCT03435939 is sponsored by University of Kansas Medical Center.

What drugs are being tested in NCT03435939?

Interventions in NCT03435939: Losartan.

What condition does NCT03435939 study?

NCT03435939 studies Cystic Fibrosis.

Is NCT03435939 still recruiting?

NCT03435939 is currently active, enrolled. Last updated 28 October 2025.

Last reviewed 2025-10-28 · How we verify

NCT03435939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

Active, enrolled EARLY_PHASE1 Last updated 28 October 2025

What this trial tests

EARLY_PHASE1 trial testing Losartan in Cystic Fibrosis in 16 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 February 2022

Primary endpoint
3 September 2025

28 February 2026

Quick facts

Lead sponsor	University of Kansas Medical Center
Phase	EARLY_PHASE1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	16
Start date	15 February 2022
Primary completion	3 September 2025
Estimated completion	28 February 2026
Sites	1 location across United States

Drugs / interventions tested

Losartan (losartan) — full drug profile →

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

University of Kansas Medical Center

Who can join

18 and older, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to execute a small clinical proof of concept trial: To examine the effects of losartan on mucociliary clearance (MCC) in patients not eligible for CFTR rescue therapies

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.
Kim MD, Baumlin N, Yoshida M, Polineni D, et al · · 2020 · cited 39× · PMID 31613648 · DOI 10.1164/rccm.201905-0990oc
Oral losartan yields subtherapeutic airway exposure compared to nebulized delivery and fails to improve mucociliary clearance in cystic fibrosis.
Bengtson CD, Schmid A, Kim MD, Dennis JS, et al · · 2026 · PMID 42158940 · DOI 10.3389/fphar.2026.1807581

Verify or expand the search:

Other trials of Losartan

Trials testing the same drug.

NCT06491940 — Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan · NA · not yet recruiting
NCT06333522 — Losartan Use to Mitigate Arthrofibrosis Following Total Joint Arthroplasty · Phase 4 · withdrawn
NCT06150560 — A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial) · Phase 3 · recruiting
NCT06108063 — Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan · Phase 1, PHASE2 · recruiting
NCT06329050 — The Effects of Losartan on Attention Control: An Eye-tracking Study · NA · recruiting

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Other University of Kansas Medical Center trials

Trials by the same sponsor.

NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03435939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
Last refreshed: 28 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03435939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing